CYP3A5 genotype has a dose-dependent effect on ABT-773 plasma levels

• Published in: Clinical pharmacology and therapeutics Vol. 75; no. 6; p. 516
• Main Authors: Katz, David A, Grimm, David R, Cassar, Steven C, Gentile, Maria C, Ye, Xin, Rieser, Matthew J, Gordon, Eric F, Polzin, Jill E, Gustavson, Linda E, Driscoll, Rita M, O'dea, Robert F, Williams, Laura A, Bukofzer, Stanley
• Format: Journal Article
• Language: English
• Published: United States 01.06.2004
• Subjects: Adolescent; Adult; Aged; Area Under Curve; Confidence Intervals; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System - genetics; Dose-Response Relationship, Drug; Double-Blind Method; Erythromycin - administration & dosage; Erythromycin - analogs & derivatives; Erythromycin - blood; Erythromycin - chemistry; Female; Genes, MDR - genetics; Genotype; Humans; Ketolides; Male; Middle Aged; Statistics, Nonparametric

The metabolizing enzyme cytochrome P450 (CYP) 3A5 is polymorphically expressed as a result of genetic variants that do not encode functional protein. Because of overlapping substrate specificity with CYP3A4 and the multidrug efflux pump P-glycoprotein, the importance of CYP3A5 genetic polymorphism f...